{
  "chapter": "Mood Disorders-Mood Disorders",
  "questions": [
    {
      "q_no": 1,
      "question": "A 45-year-old male with a history of depression and anxiety presents with worsening shortness of breath. He admits to heavy smoking over the past 20 years, which has worsened his respiratory symptoms. Despite attempts to quit, he finds smoking alleviates his anxiety. His doctor recommends cessation due to respiratory difficulties. Which medication is best for smoking cessation while addressing his depression?",
      "options": {
        "A": "Varenicline",
        "B": "Bupropion",
        "C": "Nicotine Replacement Therapy (NRT)",
        "D": "Sertraline"
      },
      "correct_answer": "B",
      "explanation": "Correct Answer: B) Bupropion Explanation: Bupropion is a dual-action medication that serves both as an antidepressant and as a smoking cessation aid. It works by inhibiting the reuptake of dopamine and norepinephrine, reducing cravings and withdrawal symptoms from nicotine. This makes it ideal for patients who suffer from depression and anxiety, like this patient, as it can manage both mood disorders and smoking cessation simultaneously. Atypical antidepressants: Category Mechanism of Action Drugs Indications Common Side Effects SARI (Serotonin Antagonist and Reuptake Inhibitors) Antagonizes serotonin receptors (5-HT2A, 5-HT2C) and inhibits serotonin reuptake Trazodone Major depressive disorder; off-label for insomnia Sedation, dizziness, dry mouth, priapism Nefazodone Major depressive disorder Hepatotoxicity, sedation, dizziness NaSSA (Noradrenergic and Specific Serotonin Antidepressants) Antagonizes presynaptic alpha-2 adrenergic receptors; blocks 5-HT2 and 5-HT3 receptors Mirtazapine Major depressive disorder, especially with insomnia Sedation, weight gain, minimal sexual side effects NDRI (Norepinephrine-Dopamine Reuptake Inhibitors) Inhibits the reuptake of norepinephrine and dopamine Bupropion Major depressive disorder, anxiety disorders, smoking cessation, Preventive treatment of seasonal affective disorder Insomnia, tremors, nausea, seizures (at high doses) minimal sexual side effects Varenicline (Option A) is a partial agonist at the nicotine receptor and is highly effective for smoking cessation by reducing cravings and withdrawal symptoms. However, it does not directly address the patient's underlying depression or anxiety, making it a less ideal option in this scenario where mood management is also crucial. Nicotine Replacement Therapy (NRT) (Option C) (e.g., nicotine patches, gums, or lozenges) is commonly used to ease nicotine withdrawal but does not address the underlying mood disorders. It",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Mood Disorders-Mood Disorders"
    },
    {
      "q_no": 2,
      "question": "A 45-year-old male suffering from depression, being treated with lithium carbonate 300 mg thrice daily, develops vomiting, abdominal pain, and dizziness. On examination, he has nystagmus, muscle weakness, and slurred speech. What would be the serum concentration of lithium to cause these symptoms?",
      "options": {
        "A": "> 2.5 mEq/L",
        "B": "1.5 to 2 mEq/L",
        "C": "2 to 2.5 mEq/L",
        "D": "0.5 to 1.2 mEq/L"
      },
      "correct_answer": "B",
      "explanation": "Correct Answer: B) 1.5 to 2 mEq/L Explanation: The clinical scenario here points to the diagnosis of mild to moderate lithium toxicity which is caused by a lithium level of 1.5 to 2 mEq/L. Lithium toxicity is a medical emergency and can cause permanent neuronal damage and death. Signs and symptoms of lithium toxicity: Mild to moderate intoxication (lithium level, 1.5–2.0 mEq/L) Gastrointestinal: Vomiting Abdominal pain Dryness of mouth Neurologic: Ataxia Dizziness Slurred speech Nystagmus Lethargy or excitement Muscle weakness Moderate to severe intoxication (lithium level: 2.0–2.5 mEq/L) (Option C) Gastrointestinal: Anorexia Persistent nausea and vomiting Neurologic: Muscle fasciculations Clonic limb movements Hyperactive deep tendon reflexes Choreoathetoid movements Convulsions Delirium Syncope Electroencephalographic changes Stupor Coma Circulatory failure: low BP, arrhythmias, and conduction abnormalities) Severe lithium intoxication (lithium level >2.5 mEq/L) (Option A) Generalized convulsions Oliguria and renal failure Death Management Discontinue lithium and treat dehydration Removal of unabsorbed lithium: Emesis, gastric lavage, and absorption with Kayexalate (sodium polystyrene sulfonate) or GoLYTELY (polyethylene glycol solution) For any patient with a serum lithium level greater than 4.0 mEq/L, hemodialysis Therapeutic level of lithium: 0.5 to 1.2 mEq/L (Option D) is the therapeutic level, but even a slightly higher amount may lead to toxicity, especially in elderly patients. For acute mania, 1 to 1.2 mEq/L is the required serum concentration and 0.4 to 0.8 mEq/L for maintenance. Serum level monitoring of lithium: Monitoring should be done regularly every 2 to 6 months. Baseline ECG study yearly. Weekly monitoring for dose adjustments, signs of toxicity, and noncompliance. Samples are taken 12 hours post-dose at steady-state (usually after 5 days of consistent dosing). Reference: Kaplan & Sadock’s Synopsis of Psychiatry, 12th Edition, Pages 2059-61, 2066-67. https://www.ncbi.nlm.nih.gov/books/NBK519062/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9886805/#",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Mood Disorders-Mood Disorders"
    },
    {
      "q_no": 3,
      "question": "Which of the following statements is true regarding lithium-induced tremors?",
      "options": {
        "A": "D2 blockers may worsen lithium tremor.",
        "B": "Coarse tremor is typical of early lithium use.",
        "C": "Fine tremor from lithium is most noticeable during rest.",
        "D": "High-dose steroids are commonly used to treat lithium tremors."
      },
      "correct_answer": "A",
      "explanation": "Correct answer: A) D2 blockers may worsen lithium tremor. Explanation: D2 blockers may exacerbate tremors when used alongside lithium. Lithium Induced Tremors: Fine Tremor: Prevalence: Tremor of the hands is a common side effect of lithium, affecting around 25% of patients. Characteristics: Lithium tremor is generally fine symmetric and resembles essential or physiologic tremor. It is most noticeable during intentional posture (e.g., writing, holding objects). (Option C) Additive Effects: Tremor severity can increase due to anxiety, alcohol withdrawal, caffeine, or idiopathic/familial tremors. D2 blockers and some antidepressants may exacerbate tremors when used alongside lithium. (Option A) Timing: Typically presents early in treatment but may appear later. In some cases, the tremor improves spontaneously after years of lithium use. Risk Factors: Higher lithium levels are associated with an increased risk of tremor. Older patients are more susceptible due to the additive effect of age-related essential tremors. Coarse Tremor: Occurs during lithium toxicity, more irregular, widespread, and severe. (Option B) Management of Tremors associated Lithium: Conservative management includes reducing caffeine intake and maintaining lithium levels in the low–medium range. Mild tremors are often tolerated by patients, but moderate or socially embarrassing tremors may require treatment. Treatment: Beta-blockers (e.g., propranolol) are the most common treatment for lithium-induced tremor (Option D). Other options include: Primidone Benzodiazepines Vitamin B6 Reference: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5164879/",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Mood Disorders-Mood Disorders"
    },
    {
      "q_no": 4,
      "question": "A patient with mood disorder is on treatment with lithium. She is suffering from pain in her hand after a sprain. Which of the following NSAIDs can be advised to this patient in this situation?",
      "options": {
        "A": "Naproxen",
        "B": "Indomethacin",
        "C": "Ibuprofen",
        "D": "Aspirin"
      },
      "correct_answer": "D",
      "explanation": "Correct Answer: D) Aspirin Explanation: The NSAID that can be advised here is aspirin as that is the only one without any interaction with lithium whereas the others cause an increase in lithium concentrations. Precautions and Adverse Effects of Lithium: Water and Salt Balance: Changes in body water and sodium levels can affect lithium excretion. Excess Sodium: High sodium intake can lower lithium concentrations. Low Sodium: Insufficient sodium (e.g., from fad diets) can lead to toxic lithium levels. Decreased body fluid (e.g., excessive sweating) can cause dehydration and lithium intoxication. Side effects of LIthium Neurologic Benign, nontoxic: Dysphoria, Lack of spontaneity, Slowed reaction time , Memory difficulties Toxic: Coarse tremor, Dysarthria, Ataxia, Neuromuscular irritability, Seizures, Coma, Death Miscellaneous: Peripheral neuropathy, Benign intracranial hypertension, Myasthenia gravis-like syndrome, Lower seizure threshold Endocrine Thyroid: Goiter, hypothyroidism , exophthalmos, hyperthyroidism Parathyroid: Hyperparathyroidism , adenoma Cardiovascular Benign T-wave changes Sinus node function Renal Concentrating defect, Morphologic changes, Polyuria (nephrogenic diabetes insipidus) , Reduced GFR, Nephrotic syndrome, Renal tubular acidosis Dermatologic Acne, Hair loss, Psoriasis, Rash Gastrointestinal Loss of appetite, Nausea, Vomiting, Diarrhea Miscellaneous Altered carbohydrate metabolism Weight gain Fluid retention Drug interactions Generally safe and effective. Higher doses of dopamine-releasing agents (DRAs) may increase: Lithium-induced neurologic side effects. Neuroleptic extrapyramidal symptoms. Rare cases of encephalopathy were reported. Interactions with Other Medications: Carbamazepine, Lamotrigine, Valproate, Clonazepam: I Li concentrations. Diuretics: Thiazide and Potassium-Sparing Diuretics: I Li concentrations. Osmotic and Loop Diuretics, Carbonic Anhydrase Inhibitors, Xanthines: I Li concentrations. ACE Inhibitors: I Li concentrations. Angiotensin II Receptor Inhibitors (e.g., Losartan, Irbesartan): Do not affect lithium concentrations. NSAIDs: Many (e.g., Indomethacin, Ibuprofen, Naproxen ) can I Li concentrations (decrease lithium clearance). (Option A, B & C) Aspirin and Sulindac: Do not affect lithium concentrations. Quetiapine (Seroquel): May cause somnolence but is generally well tolerated. Ziprasidone (Geodon): May modestly increase the incidence of tremors. Calcium Channel Inhibitors: Avoid coadministration due to the risk of fatal neurotoxicity. Electroconvulsive Therapy (ECT): Discontinue lithium 2 days before ECT to reduce delirium risk. Reference: Kaplan & Sadock’s Synopsis of Psychiatry, 12th Edition, Pages 2054-55, 2063",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Mood Disorders-Mood Disorders"
    },
    {
      "q_no": 5,
      "question": "A patient with major depressive disorder is advised with lithium therapy. Which of the following statements is false about lithium? I CO I )",
      "options": {
        "A": "The commonly used form is lithium carbonate (Li",
        "B": "Lithium modulates levels of neurotransmitters and neuropeptides.",
        "C": "Lithium is a drug only used for the treatment of psychiatric conditions",
        "D": "Lithium is rapidly and completely absorbed on oral administration"
      },
      "correct_answer": "C",
      "explanation": "Correct Answer: C) Lithium is a drug only used for the treatment of psychiatric conditions disorders like epilepsy, hematological like aplastic anemia, endocrine like thyroid cancer, etc. Lithium: Dosage form: Commonly used as lithium carbonate (Li I CO I ). (Option A) Pharmacokinetics Absorption: rapid and complete after oral administration; peak serum levels in 1–1.5 hours (standard) and 4–4.5 hours (slow-release). (Option D) Pregnancy: Excretion increases during pregnancy, decreases post-delivery, and is excreted in breast milk. Mechanisms of Action Mood Stabilization: the exact mechanism is unclear; theories include: Ion transport: alterations in ion transport across cell membranes. Neurotransmitter effects: modulate levels of neurotransmitters and neuropeptides. (Option B) Signal transduction: influences signal transduction pathways and second messenger systems. Uses of Lithium Psychiatric uses Nonpsychiatric uses * Well-established (FDA approved): Bipolar disorder Evidence benefit in particular groups: Schizophrenia Aggression (episodic), explosive behavior, and self-mutilation Conduct disorder in children & adolescents Cognitive disorders Intellectual disability Aggressive prisoners Anecdotal, controversial, unresolved, or doubtful: Alcohol and substance-related disorders PTSD OCD ADHD Phobias Eating disorders Cocaine abuse Sexual disorders Transvestism Exhibitionism Pathologic hypersexuality Personality disorders Neurologic Epilepsy Headache Huntington disease Hematologic Aplastic anemia Cancer- chemotherapy-induced/ radiotherapy-induced Felty syndrome Endocrine Thyroid cancer Cardiovascular Antiarrhythmic agent Dermatologic Genital herpes Eczematoid & seborrheic dermatitis Gastrointestinal Cyclic vomiting Gastric ulcers Pancreatic cholera Ulcerative colitis Respiratory Asthma Cystic fibrosis Other Bovine spastic paresis *(Do not have FDA approved labeling) Reference: Kaplan & Sadock’s Synopsis of Psychiatry, 12th Edition, Pages 2047-48, 2051-54",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Mood Disorders-Mood Disorders"
    },
    {
      "q_no": 6,
      "question": "A 15-year-old child is brought to the psychiatric department for attempting suicide. On further questioning, he states that one of his peers in school died of suicide, followed by which a few of the others, including him, attempted the same method. What is this condition called?",
      "options": {
        "A": "Copycat suicide",
        "B": "Paradoxical suicide",
        "C": "Parasuicide",
        "D": "Major depressive disorder"
      },
      "correct_answer": "A",
      "explanation": "Correct Answer: A) Copycat suicide Explanation: The condition here is copycat sui cide where o ne individual’s suicidal behavior influences others within the same peer group to attempt suicide. It can be due to an influence from a famous personality as well. Modified SAD PERSONS Score: Mnemonic for 10 criteria for assessment of potential suicidal behavior. Letter Criteria Number of Points Assigned S S ex: Male 1 A A ge: <19 or >45 years 1 D D epression or hopelessness 2 P P revious attempts or psychiatric care 1 E E xcessive alcohol or drug use 1 R R ational thinking loss 2 S S eparated/divorced/widowed 1 O O rganized or serious attempt 2 N N o social supports 1 S S tated future intent 2 Patients with a score of ≤ 5: Outpatient psychiatric evaluation Patients with a score of ≥ 6: Emergent psychiatric consultation and a possible hospital admission Protective Factors: Secure connections to school and peers can mitigate risk, even with other risk factors. Paradoxical suicide (Option B) Copycat suicide Parasuicide (Option C) Patients recovering from suicidal depression are at increased risk as their mood improves. Gaining energy can lead to the ability to act on suicidal plans which is known as paradoxical suicide. Some individuals may suddenly appear at peace, indicating a hidden decision to commit suicide. Clinicians should be vigilant regarding significant changes in behavior, as they may signal an impending suicide attempt. Copycat suicide refers to the phenomenon where one individual’s suicidal behavior influences others within the same peer group to attempt suicide. Clusters of suicides can occur among adolescents who know each other or attend the same school. Suicidal behavior in one adolescent can lead to subsequent attempts by peers through identification. Media Influence : Certain media portrayals, especially of adolescent suicide, can lead to transient increases in suicide attempts. The phenomenon known as \"Werther syndrome\" illustrates how publicized suicides can inspire imitative behavior among vulnerable individuals. Historical Context : The term \"Werther syndrome\" originates from Goethe's novel The Sorrows of Young Werther , which led to a spike in suicides among young men after its publication. Impact of exposure: Direct exposure to a peer’s suicide is more likely to result in increased risks of depression and PTSD rather than directly causing more suicides. A parasuicide is nothing but an attempted suicide. History of parasuicide significantly increases suicide risk by up to 40 times, remaining elevated for up to 20 years. Highest risk of suicide occurs within the first months post-psychiatric care, with elevated risk persisting for 1-2 years after parasuicide. More severe and frequent parasuicide attempts indicate higher risk;",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Mood Disorders-Mood Disorders"
    },
    {
      "q_no": 7,
      "question": "A 25-year-old woman visits her doctor 3 weeks postpartum. She reports feeling persistently sad, irritable, and exhausted, has trouble sleeping, and has lost interest in activities she once enjoyed. She also confides that she has thoughts of not wanting to be alive but hasn't acted on them. What condition is she most likely experiencing?",
      "options": {
        "A": "Postpartum Blues",
        "B": "Postpartum Psychosis",
        "C": "Postpartum Depression",
        "D": "Postpartum Anxiety"
      },
      "correct_answer": "C",
      "explanation": "Correct Answer: C)Postpartum Depression Explanation: Symptoms such as depressed mood, irritability, insomnia, lack of interest in usual activities (anhedonia), and suicidal thoughts at three weeks postpartum indicate a diagnosis of Postpartum Depression. Postpartum Blues (Option A) Postpartum Depression (Option C) Postpartum Psychosis (Option B) Occurrence Affects up to 80% of women after childbirth Affects 10- 15% of women 70% risk of recurrence in next pregnancy Incidence is about 1-2 in 1000 deliveries 50% risk of recurrence in next pregnancy Timing Onset 3-5 days postpartum, resolves by days to weeks Within the first 6 weeks postpartum or after abortion Symptoms appear within 2-3 weeks postpartum, last 2-3 months Symptoms Transient symptoms such as Emotionally labile Insomnia Weepiness Loss of energy Depressed mood Loss of interest or pleasure (anhedonia) Loss of appetite Insomnia Social withdrawal Irritability Suicidal thoughts Initial symptoms: insomnia, tearfulness, mood lability, fatigue, followed by Hallucinations Delusions Risk Factors Not specific; linked to biochemical changes Young maternal age Antenatal depression Family history of mood disorder Unmarried status Smoking Stress Newborns in intensive care Physical or verbal abuse Serious adverse obstetrical events Nulliparas Obstetrical complications Family history of mood disorder History of psychotic illness Treatment Supportive treatment and reassurance Antidepressants and psychotherapy Hospitalization, pharmacological treatment (lithium, antipsychotics, antidepressants), long-term psychiatric care Temporary separation from the infant and nursing supervision may be necessary Brexanolone: New FDA (in 2019) approved drug for the treatment of postpartum depression. Intravenous formulation of allopregnanolone administered over 60 hours. It is a neuroactive steroid and functions as an allosteric modulator of GABA I . Zuranolone/ Zurzuvae: First FDA approved oral medication indicated to treat postpartum depression (PPD) in adults. Postnatal Anxiety (Option D) negatively affects breastfeeding, early interactions, infant temperament, sleep, and cognitive development, while the symptoms of persistent sadness, irritability, and suicidal thoughts are more indicative of postpartum depression. Reference: DC Dutta’s Textbook of Obstetrics, 9th Edition, Page 415 William’s Obstetrics, 26th Edition, Pages 1144,1145,1146,1148 Kaplan & Sadock’s Synopsis of Psychiatry, 12th Edition, Page 391 https://www.ncbi.nlm.nih.gov/books/NBK519070/",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Mood Disorders-Mood Disorders"
    },
    {
      "q_no": 8,
      "question": "A 28-year-old woman presents with significant mood swings, irritability, and a lack of interest in her usual activities in the week before her period. She also mentions difficulty in falling asleep, breast tenderness and easy fatigability. These symptoms improve shortly after her period begins and minimal in the week post menses. What condition is she most likely experiencing?",
      "options": {
        "A": "Dysthymia",
        "B": "Cyclothymia",
        "C": "Premenstrual Syndrome",
        "D": "Premenstrual Dysphoric Disorder"
      },
      "correct_answer": "D",
      "explanation": "Correct Answer: D) Premenstrual Dysphoric Disorder Explanation: Presence of at least five specific symptoms , including mood swings, irritability, lack of interest, insomnia and easy fatigability, that occur in the luteal phase and resolve after menstruation , align with diagnosis of Premenstrual Dysphoric Disorder (PMDD). Premenstrual Dysphoric Disorder (PMDD): Definition Characterized by debilitating mood and behavioral change in the week preceding menstruation (luteal phase) that interferes with normal functioning. Disappears within a few days of the onset of menses. Diagnosis At least 5 of the following symptoms must be present: Affective lability (e.g., mood swings) Irritability or anger or increased interpersonal conflicts Depressed mood, feeling of hopelessness, or self-deprecating thoughts Anxiety, tension and/or feeling of being keyed up or on edge Decreased interest in usual activities (e.g., work, school) Difficulty in concentration Lethargy, easy fatigability, or marked lack of energy Change in appetite; overeating; specific food cravings Hypersomnia or insomnia Sense of being overwhelmed or out of control Physical Symptoms: Breast tenderness or swelling Joint or muscle pain Sensation of bloating Weight gain Diagnosis: Confirmed if these symptoms present for at least 2 symptomatic cycles. Differential Diagnosis Premenstrual Syndrome (PMS) (Option C) Dysmenorrhea Bipolar disorder, major depressive disorder, and dysthymia Treatment SSRI: Citalopram, escitalopram, fluoxetine, paroxetine and sertraline Benzodiazepines: Alprazolam PMS vs PMDD: Features PMS PMDD Severity of symptoms Mild to moderate Severe Mood symptoms Persistent, but not dominant Severe emotional & mood symptoms dominate Functional impairment Minimal to mid; daily life remains manageable Significant; affects work, social, and personal life DSM-5 diagnostic criteria No specific criteria Requires at least 5 symptoms Dysthymia (Dysthymic Disorder/Persistent Depressive Disorder): (Option A) Chronic mild depressive symptoms lasting most of the day and almost continuously. According to DSM-5 , persistent depressive disorder is diagnosed when depressive symptoms persist for 2 or more years (or 1 year for children ), with no symptom-free periods lasting longer than 2 months during the illness. Double depression: Diagnosed if, after the initial 2 years of dysthymia, a person then suffers from major depressive episodes. Cyclothymia: (Option B) Milder form of bipolar disorder . According to DSM-5, cyclothymic disorder is characterized by depressive and hypomanic symptoms lasting at least 2 years (or",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Mood Disorders-Mood Disorders"
    },
    {
      "q_no": 9,
      "question": "A 32-year-old woman with a history of bipolar disorder (BD) is planning to conceive. She has been stable on her current medication but is concerned about the risks to her future child. Which of the following is the safest drug for managing BD during pregnancy?",
      "options": {
        "A": "Lithium",
        "B": "Valproate",
        "C": "Lamotrigine",
        "D": "Carbamazepine"
      },
      "correct_answer": "C",
      "explanation": "Correct Answer: C) Lamotrigine Explanation: Lamotrigine is considered one of the safest medications for pregnant individuals with bipolar disorder, with a low risk of fetal malformations and no adverse effects on postpartum cognitive development. Treatment of Bipolar Disorder (BD) in Pregnancy: The safety of pharmacotherapeutic agents for treating bipolar disorder must be considered in terms of the following: Teratogenicity Poor neonatal adaptation Long-term neurobehavioral sequelae Medication Potential Fetal/Newborn risk Clinical Recommendation Mood Stabilizers Lithium (Option A) Low risk of Ebstein’s anomaly: 1 in 1000 with first-trimester exposure No evidence of behavioral or cognitive problems in children exposed to lithium till 5 years of age Fetal echocardiography Frequent serum lithium monitor in view of fluid shifts over pregnancy Should be well hydrated to reduce chances of lithium toxicity Valproic acid (Option B) Increased rate of congenital malformations (approximate 10%), including neural tube defects Linked to neurodevelopmental disorders in children with in-utero exposure Must be avoided in favor of safer agents Prior to conception, women with BD preferably to be shifted to another safer prophylactic agent High-dose folic acid supplementation (4 mg/day) advised prior to conception Carbamazepine (Option D) Congenital malformations: Around 3%–6% Neural tube defect, cleft palate, fingernail hypoplasia Risk of bleeding diathesis in neonates due to Vitamin K deficiency If possible, use in pregnancy should be avoided High-dose folic acid supplementation (4 mg/day) advised prior to conception Oral Vitamin K (20mg/day) supplementation in the last month of pregnancy in women taking carbamazepine Parenteral Vitamin K (1mg IM) supplementation for newborn, shortly after birth. Lamotrigine (Option C) Risk of major congenital malformations (2%–3%) No significant neurobehavioral sequelae Preferred safer agent to use in pregnancy Dose may be increased due to enhanced clearance rates across pregnancy stages Other Drugs for Bipolar Disorder Safe in Pregnancy First Generation Antipsychotics (FGA): Haloperidol, Trifluoperazine Second Generation Antipsychotics (SGA): Olanzapine, quetiapine, aripiprazole Selective Serotonin Reuptake Inhibitors (SSRI): Fluoxetine, escitalopram, sertraline, fluvoxamine Reference: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043818/ https://pubmed.ncbi.nlm.nih.gov/22594849/",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Mood Disorders-Mood Disorders"
    },
    {
      "q_no": 10,
      "question": "A 31-year-old male with bipolar disorder often engages in impulsive behaviors during manic episodes and struggles with depressive episodes afterwards. He attends therapy sessions where he is taught skills to manage his symptoms, improve interpersonal skills, build routine and recognize patterns in his mood changes. Which therapy would best address his needs?",
      "options": {
        "A": "Cognitive-behavioral therapy (CBT)",
        "B": "Family-Focused Therapy (FFT)",
        "C": "Interpersonal & Social Rhythm Therapy (IPSRT)",
        "D": "Acceptance and Commitment Therapy (ACT)"
      },
      "correct_answer": "C",
      "explanation": "Correct answer: C) Interpersonal & Social Rhythm Therapy (IPSRT) Explanation: Interpersonal & Social Rhythm Therapy (IPSRT) is the most appropriate choice for this patient as it directly addresses the dual challenges of managing impulsivity during manic episodes, improve interpersonal skills, build routine and recognizing mood patterns to mitigate depressive episodes, aligning closely with his treatment needs. Acute Bipolar Depression Treatment: Lithium Anticonvulsants: Lamotrigine, valproate Antipsychotics: Quetiapine (Best evidence for efficacy) , olanzapine, lurasidone, cariprazine Antidepressants: May induce mania , but some antidepressants (e.g., fluoxetine) may be useful in combination with mood stabilizers but should not be used as monotherapy. Electroconvulsive Therapy (ECT): Effective in treatment-resistant cases or where there is a strong suicidal tendency. Maintenance and Psychosocial Therapies: Maintenance Treatment : Goal : Prevent recurrences without causing unwanted side effects like sedation, weight gain, or cognitive impairment. Key Medications: Lithium, carbamazepine, valproic acid, and lamotrigine (better for depressive phases). Psychotherapy: Essential for treatment adherence and emotional stability. Therapy Type Conceptualization of Disorder Etiology Interventions Cognitive- Behavioral Therapy (CBT) (Option A) Biological vulnerability interacting with stress, along with a lack of skills , limits the ability to manage symptoms effectively. Identify and challenge automatic thoughts, Engage in rewarding activities for routine and stability Practice communication skills with providers Interpersonal & Social Rhythm Therapy (Option C) Interpersonal vulnerabilities from early attachment and learned relationship patterns, disrupting social rhythms Develop awareness of relationship patterns Track and stabilize social rhythms . Interpersonal skills training, communication analysis Family-Focused Therapy (Option B) Biological vulnerability worsened by negatively expressed emotions in the family environment Education on disorder and risk factors, establishing a relapse prevention plan with family, Communication and problem-solving skills training CBT (Option A) addresses cognitive distortions and negative thought patterns. While effective for symptom management, it does not specifically target social rhythms FFT (Option B) educates families about bipolar disorder and improves communication within the family. It does not directly address individual mood management, or impulsive behaviors. ACT (Option D) promotes psychological flexibility and acceptance of",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Mood Disorders-Mood Disorders"
    },
    {
      "q_no": 11,
      "question": "A 40-year-old woman with a history of bipolar disorder is brought to the hospital with severe agitation, grandiosity, and hyperactivity. The patient’s manic episode has not responded to lithium monotherapy, and her condition continues to deteriorate. What would be an appropriate next step in management?",
      "options": {
        "A": "Add haloperidol to lithium",
        "B": "Switch to carbamazepine monotherapy",
        "C": "Continue lithium and add divalproex",
        "D": "Administer chlorpromazine"
      },
      "correct_answer": "C",
      "explanation": "Correct answer: C) Continue lithium and add Divalproex Explanation: When lithium monotherapy fails to control acute mania, the next appropriate step is to use combination with antipsychotics like olanzapine, risperidone. Since this is not mentioned in the options, add divalproex (valproate) as a second-line combination therapy. This combination is effective in managing manic symptoms when monotherapy is insufficient. Pharmacologic Treatment of Acute Mania First line Monotherapy : Lithium , divalproex, and atypical antipsychotics such as olanzapine, risperidone, quetiapine, aripiprazole, cariprazine, asenapine, paliperidone, iloperidone, ziprasidone. Adjunctive therapy with lithium or divalproex: Risperidone, quetiapine, olanzapine, aripiprazole, asenapine Second line Monotherapy: Carbamazepine , electroconvulsive therapy (ECT), haloperidol. Combination therapy: Lithium + divalproex (Option C) Third line Monotherapy : Chlorpromazine , Clozapine, Tamoxifen Combination therapy: lithium or divalproex + haloperidol, lithium + carbamazepine, adjunctive tamoxifen Novel agent: Endoxifen: for acute mania in Bipolar I disorder Metabolite of tamoxifen. MOA: Protein kinase C (PKC) inhibitor Mood stabilizers: Lithium: It remains a cornerstone in mood stabilization, with therapeutic levels ranging from 0.6 to 1.2 mEq/L . However, due to its side effects and the need for frequent monitoring, newer drugs are often preferred in acute settings. Anticonvulsants: Valproate (divalproex) is now more commonly used than lithium for acute mania . Carbamazepine. Add haloperidol to lithium (Option A) : Haloperidol is a third-line option due to its side effect profile (e.g., extrapyramidal symptoms), and is typically reserved for patients who have not responded to second-line treatment. Switch to carbamazepine monotherapy (Option B) : While carbamazepine can be used as a second-line monotherapy, the scenario calls for augmentation, not switching, making the addition of Divalproex a more appropriate choice. Administer chlorpromazine (Option D) : Chlorpromazine is a third-line treatment for acute mania and is not preferred due to its sedative effects and risk of tardive dyskinesia. Reference: Kaplan and Sadock’s Synopsis of Psychiatry, 12th Edition, Pages 1198-1200",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Mood Disorders-Mood Disorders"
    },
    {
      "q_no": 12,
      "question": "A 32-year-old female presents with a history of frequent mood swings over the past year. She reports episodes of depression lasting several weeks, followed by periods of elevated mood where she feels overly energetic and needs very little sleep. She has had at least five of these episodes in the past 12 months. She is currently on an antidepressant. What is the next best step in her management?",
      "options": {
        "A": "Increase the dose of fluoxetine",
        "B": "Add lithium + fluoxetine",
        "C": "Withdraw the antidepressant and add valproate",
        "D": "Prescribe a higher dose of the antidepressant and add a mood stabilizer"
      },
      "correct_answer": "C",
      "explanation": "Correct answer: C) Withdraw the antidepressant and add valproate Explanation: The patient’s five distinct mood episodes in the past year indicate rapid cycling bipolar disorder, likely worsened by her antidepressant use. Withdrawing the antidepressant and initiating mood stabilizers like lithium and valproate or lamotrigine is essential to stabilize her mood and prevent mania. Rapid cycling bipolar disorder: Rapid cycling involves experiencing at least four mood episodes (manic, depressive, or hypomanic) within 1 year . A minimum 2-month period of partial or full remission must occur between episodes . It is more common with bipolar II disorder than bipolar I disorder. More common in females , typically accompanied by depressive and hypomanic episodes. Factors favoring occurrence of Rapid cycling: Long term, aggressive antidepressant usage Hypothyroidism Menopause Temporal lobe dysrhythmias Circadian rhythm disturbances Kindling Substance abuse Management: Withdrawal of antidepressant Evaluate possible precipitant( hypothyroidism, external stressors) Mood stabilizers like Valproate (DOC) / lamotrigine Antipsychotics Increase the dose of fluoxetine (Option A) : Increasing the dose of the antidepressant (fluoxetine) could exacerbate her mood instability and potentially trigger manic episodes, especially in rapid cycling bipolar disorder. Add lithium + fluoxetine (Option B) : Combining lithium with an antidepressant like fluoxetine may not be safe in a patient with rapid cycling bipolar disorder, as antidepressants can provoke mania. A more effective approach is to withdraw the antidepressant altogether. Prescribe a higher dose of the antidepressant and add a mood stabilizer (Option D) : Although adding a mood stabilizer is appropriate, increasing the antidepressant dose could further exacerbate the rapid cycling.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Mood Disorders-Mood Disorders"
    },
    {
      "q_no": 13,
      "question": "A 28-year-old male presents with excessive talkativeness, distractibility, and overconfidence for the past 5 days. He has been making impulsive decisions and seems elated. However, he is functioning well at his job and does not require hospitalization. What is the most likely diagnosis?",
      "options": {
        "A": "Hypomania",
        "B": "Mania",
        "C": "Mixed Episode",
        "D": "Cyclothymia"
      },
      "correct_answer": "A",
      "explanation": "Correct answer: A) Hypomania Explanation: The patient has symptoms of hypomania (elation, impulsivity, and distractibility) lasting for 5 days , with no marked impairment in functioning, consistent with the diagnostic criteria for hypomania. Diagnostic criteria for Mania M ood Changes: Elation/ irritability Persistently increased E nergy + ≥ 3 of the following symptoms (4 if irritable mood) for at least 1 week : D istractibility. I mpulsivity/ high-risk activities G randiosity/ Inflated Self-Esteem F light of Ideas (Racing and expansive thoughts) A ctivity increased (Hyperactivity) S leep deficit (decreased need for sleep) T alkativeness/ Pressured speech Mania with Psychotic Symptoms: May include delusions or hallucinations . Can be mood-congruent or mood-incongruent. Mood-congruent: When psychotic symptoms are mood-congruent, the content of a person’s delusions or hallucinations aligns with the person’s mood state. Mood-incongruent: The content of a person’s delusions or hallucinations does not match their mood. Hypomania (Option A) Symptoms are similar to mania but less severe . NO Marked impairment in functioning and NO hospitalization necessitated No psychotic symptoms Flight of ideas usually not seen Duration of hypomania is ≥ 4 days . Mixed Episode : Manic and depressive symptoms alternate throughout the day. Duration is ≥ 7 days . Mania (Option B) is more severe than hypomania, involving significant functional impairment or the need for hospitalization. Here, the patient is functioning well. Mixed Episode (Option C) involves simultaneous symptoms of mania and depression. The patient has no depressive symptoms. Cyclothymia (Option D) is characterized by chronic mood fluctuations over at least 2 years, including periods of hypomanic and depressive symptoms. The patient’s symptoms have lasted only 5 days and do not include depressive episodes. Reference: Kaplan and Sadock’s Synopsis of Psychiatry, 12th Edition, Page 1180, 1182 https://www.verywellhealth.com/mood-congruent-examples-and-behavior-in-bipolar-disorder-5205363",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Mood Disorders-Mood Disorders"
    },
    {
      "q_no": 14,
      "question": "A 28-year-old woman has had multiple episodes of feeling euphoric, highly energetic, and needing little sleep lasting 3-4 days. However, her symptoms never impair her work or social functioning. She has also had episodes of prolonged low mood and anhedonia lasting several weeks. What is the most likely diagnosis?",
      "options": {
        "A": "Bipolar I Disorder",
        "B": "Bipolar II Disorder",
        "C": "Cyclothymic Disorder",
        "D": "Major Depressive Disorder"
      },
      "correct_answer": "B",
      "explanation": "Correct answer: B) Bipolar II Disorder Explanation : The presence of hypomanic episodes (euphoria without significant impairment) alongside depressive episodes indicates Bipolar II Disorder . Bipolar disorder : Bipolar disorder is a type of mood disorder characterized by episodes of depression, mania, hypomania, mixed episodes. Even a single episode of mania is considered bipolar disorder. ICD-11 classifies two types of bipolar disorder. Bipolar I Disorder Bipolar II Disorder Characterized by at least 1 episode of mania and 1 episode of depression Characterized by at least 1 episode of hypomania and 1 episode of depression (Option B) M=F F>M Mean age of onset is 30yrs Mean age of onset is slightly higher Epidemiology Annual incidence is less than 1% . Equal prevalence of Bipolar I disorder in men and women . Manic episodes are more common in men . Depressive episodes are more common in women . Women are more prone to mixed episodes and rapid cycling . Age of Onset: Onset ranges from 5 to 50 years, with a mean age of 30 . Prevalence in adolescents rises from 2% at ages 13-14 to 4% by age 18 . Socioeconomic Factors: Higher incidence in divorced or single individuals. More common in upper socioeconomic groups and non-college graduates. Genetics Family history increases the risk for mood disorders. 1st-degree relatives have a 10-fold risk of developing bipolar disorder. Genetic overlap with schizophrenia , especially on chromosomes 18q and 22q. Brain Imaging Increased hyperintensities in subcortical areas (basal ganglia, thalamus) in bipolar I disorder . Imaging studies show increased dopamine transporter levels. Functional imaging shows abnormal brain activation, with hyperactivity in frontal areas and hypoactivity in the amygdala and basal ganglia . Bipolar I Disorder (Option A) : Requires at least one manic episode causing significant impairment or psychosis. Since the patient has only experienced hypomania, this diagnosis is incorrect. Cyclothymic Disorder (Option C) : Involves periods of hypomanic and depressive symptoms that don’t meet full criteria for either, lasting at least 2 years. Major Depressive Disorder (Option D) : Involves only depressive episodes without any history of hypomanic or manic episodes.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Mood Disorders-Mood Disorders"
    },
    {
      "q_no": 15,
      "question": "A 16-year-old female patient recently separated from her boyfriend presents with severe depression with suicidal ideation and has attempted self-harm by slitting her wrist. What is the best possible management care offered to the patient in this situation?",
      "options": {
        "A": "Cognitive Behavioral Therapy (CBT)",
        "B": "Electroconvulsive Therapy (ECT)",
        "C": "Selective Serotonin Reuptake Inhibitors (SSRIs)",
        "D": "Family Therapy"
      },
      "correct_answer": "B",
      "explanation": "Correct Answer: B) Electroconvulsive Therapy (ECT) Explanation: Electroconvulsive Therapy (ECT) is indicated for providing rapid relief of suicidal ideation in patients experiencing severe depression . It is also effective for treatment-resistant depression that does not respond to multiple antidepressant trials. Additionally, ECT is beneficial for severe psychosis, food refusal secondary to depression, catatonia, bipolar depressive and manic patients. Treatment Approaches for Depression: Type of Therapy Description Indication Combination Therapy Pharmacotherapy + Psychotherapy Combines medications (e.g., antidepressants) with psychotherapy for a higher response rate. Moderate to severe depression Single Therapy Psychotherapy alone may be sufficient for mild cases. Mild depression Psychotherapy : Psychotherapy Type Description Focus Cognitive Behavioral Therapy (CBT) (Option A) Evidence-based therapy focusing on correcting cognitive distortions and maladaptive behaviors. Developing healthier thought patterns and coping strategies. Interpersonal Therapy (IPT) Addresses current interpersonal problems, including family dynamics and relationship issues. Enhancing social support and resolving conflicts. Family Therapy (Option D) Involves family members to improve communication and resolve conflicts. Family dynamics and relationships. Psychoanalytically Oriented Therapy Uncovers unconscious motivations and past experiences affecting behavior. Insight into past influences on current behavior. Behavior Therapy Utilizes reinforcement techniques to modify problematic behaviors. Behavior modification and improvement. Somatic Treatments : Treatment Mechanism/Procedure Indication Considerations Electroconvulsive Therapy (ECT) Induces controlled seizures under anesthesia and muscle relaxant. Used to rapidly alleviate severe depressive symptoms. Severe depression, especially with suicidal risk or psychotic features. Safe for pregnant patients. Transcranial Magnetic Stimulation (TMS) Uses short pulses of magnetic energy to stimulate brain nerve cells involved in mood regulation. Patients unresponsive to at least one antidepressant. Non-invasive, no anesthesia required. Vagal Nerve Stimulation (VNS) The electrodes are implanted to stimulate the left vagus nerve and regulate mood. Chronic or treatment-resistant depression. Considered after other treatments have failed. Deep Brain Stimulation (DBS) Implantation of leads in specific brain areas associated with mood regulation. Chronic or intractable depression. Considered after multiple treatment failures. Phototherapy Uses bright light (1500-10,000 Lux) from a specialized lightbox for 1 to 2 hours",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Mood Disorders-Mood Disorders"
    },
    {
      "q_no": 16,
      "question": "A 45-year-old male with a history of severe depression was involved in a construction accident where a nail gun discharged and injured his jaw. As a result, he now experiences significant feeding difficulties. What alternative treatment options available for intranasal administration can be provided to manage his condition?",
      "options": {
        "A": "Esketamine",
        "B": "Fluoxetine",
        "C": "Lithium",
        "D": "Trazodone"
      },
      "correct_answer": "A",
      "explanation": "Correct Answer: A) Esketamine Explanation: Esketamine is an NMDA receptor antagonist approved for treatment-resistant depression. It is administered intranasally , making it suitable for patients who cannot take oral medications due to feeding difficulties, such as this patient with a jaw injury. It is a rapidly acting S enantiomer of ketamine. Novel Agents: Medication Mechanism of Action Indications Route of Administration Common Side Effects Esketamine NMDA receptor antagonist; modulates glutamate Treatment- resistant depression Nasal spray Sedation, dissociation; requires monitoring Gepirone Agonist/ partial agonist at 5HT1A Major depressive disorder Oral Dizziness, nausea, insomnia, abdominal pain. C/I in Prolonged QTc interval (>450 msec) or congenital long QT syndrome GABA Modulators: Bexanolone Zuranolone GABA-A receptor positive allosteric modulator (synthetic analogue of neuroactive steroid allopregnanolone) Postpartum depression Brexanolone- iv Zuranolone- oral Drowsiness, dizziness, diarrhea. Advice not to drive or engage in hazardous activities at least 12 hours after administration. Monitoring: Patients receiving Esketamine should be observed for at least 2 hours post-administration for sedation and dissociation effects. Combination: Often used in conjunction with oral antidepressants. Fluoxetine (Option B) is an SSRI commonly used to treat depression. However, it is typically administered orally, which may be problematic for this patient due to his feeding difficulties. Additionally, it has a slower onset of action compared to Esketamine. Lithium (Option C) is often used as a mood stabilizer, particularly in bipolar disorder, but it also requires oral administration. Lithium also necessitates regular blood monitoring due to its narrow therapeutic index, which may complicate treatment in this patient, given his current physical condition. Electroconvulsive therapy (ECT) (Option D) is an option for severe depression, but it is usually reserved for cases where other treatments fail or in acute emergencies. Esketamine provides a less invasive option that can be considered earlier in treatment. Reference: Goodman and Gilman Pharmacological Basis of Therapeutics, 14th Edition, Pages 352, 354 Kaplan and Sadock’s Synopsis of Psychiatry, 12th Edition, Page 1255",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Mood Disorders-Mood Disorders"
    },
    {
      "q_no": 17,
      "question": "A 35-year-old man lost his spouse a year ago and has been experiencing depressive disorder. He is consistent with his medications and shows improvement. Which of the following statements is incorrect about the biological factors that contribute to depression?",
      "options": {
        "A": "Neurogenesis hypothesis states that brain abnormalities cause depression",
        "B": "Deficiency or dysregulation of brain monoamines leads to depressive symptoms",
        "C": "The atrophy of already-developed neurons can cause depression",
        "D": "Brain dysfunction affecting the amygdala or hippocampus plays no role in depressive disorders"
      },
      "correct_answer": "D",
      "explanation": "depressive disorders Correct Answer: D) Brain dysfunction affecting the amygdala or hippocampus plays no role in depressive disorders Explanation: Brain dysfunctions affecting the amygdala , hippocampus , prefrontal cortex , and anterior cingulate cortex are factors that lead to depressive disorder in many cases. Epidemiology of Depressive Disorders: General trend: Prevalence increases with age. Females > males (Children: Boys = Girls). Mean age of onset (40 yrs) May be more common in Rural > Urban areas Low socio-economic status > High socio-economic status 20% experience major depression by age 18. Family History: ~3 times higher risks if a first-degree relative has major depression. Persistent Depressive Disorder/Dysthymia/Dysthymic Disorder: According to DSM-5 , persistent depressive disorder is diagnosed when depressive symptoms persist for 2 or more years (or 1 year for children ), with no symptom-free periods lasting longer than 2 months during the illness. Double Depression: ~9.9% develop major depression within 6 months of persistent depressive disorder. Etiology of Depressive Disorders: Environmental factors Biological factors Acute negative life events Many cases are preceded by such events Loss of a significant person or relation like a spouse Immigrant or refugees due to loss, isolation, and trauma of migration Chronic stress: Poverty, unemployment, single motherhood, poor housing, poor residential conditions, parents of disabled children Childhood adversity: Early exposure to trauma (loss of a parent) Social and institutional barriers: Racism, discrimination, and socioeconomic status Monoamine hypothesis : deficiency or dysregulation of brain monoamines leads to depressive symptoms (Option B) Neuroendocrine: HPA axis hyperactivity Hypercortisolemia Undetected thyroid dysfunction Low brain - derived neurotropic factor Neurotransmitter deficits: Norepinephrine : decreased sensitivity of beta-adrenergic receptors Low serotonin precipitates depression Dopamine may be reduced Decreased GABA levels due to chronic stress Decreased 5-hydroxy indole acetic acid (5-HIAA) Increased level of ACh and glutamate. Brain dysfunction affecting the amygdala, hippocampus, prefrontal cortex, and anterior cingulate cortex Neurogenesis hypothesis stating brain abnormalities causing depression is due to developmental anomalies leading to a deficiency of neurons (Option A) Neuroplasticity hypothesis states that the atrophy of already-developed neurons can cause depression (Option C) Immune system processes Chronic stress may activate immune responses (CRF, cytokines, and interleukins), leading to inflammation. Elevated proinflammatory cytokines (IL-6, CRP), indicate a bidirectional relationship",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Mood Disorders-Mood Disorders"
    },
    {
      "q_no": 18,
      "question": "A 36-year-old divorced man with a history of depression is being treated with moclobemide; on the day of his wedding anniversary, he starts reminiscing about his ex-wife and consumes a large quantity of red wine. Shortly afterwards, he presents with severe headaches, palpitations, sweating, and hypertension. What is the most appropriate management for this patient?",
      "options": {
        "A": "Wait for 30 minutes for symptoms to resolve on their own",
        "B": "Intravenous Phentolamine",
        "C": "Discontinuation of moclobemide and administration of intravenous fluids",
        "D": "Intravenous Labetalol"
      },
      "correct_answer": "B",
      "explanation": "Correct Answer: B) Intravenous Phentolamine Explanation: The patient is experiencing a hypertensive crisis due to the \"cheese reaction,\" where tyramine from red wine interacts with moclobemide, a monoamine oxidase inhibitor ( MAOI), leading to excessive norepinephrine release resulting in hypertensive crisis. Intravenous phentolamine is the most appropriate treatment, as it rapidly lowers blood pressure by blocking norepinephrine effects. Monoamine Oxidase Inhibitors (MAOIs): Types Irreversible, Non-Selective MAOIs: Phenelzine Tranylcypromine Isocarboxazid Reversible MAO-A Inhibitors: Moclobemide MAO-B Inhibitors: Selegiline Rasagiline Primary Use Depression (especially atypical depression) Other Uses Anxiety disorders, panic disorder, social phobia, treatment-resistant depression, Parkinson’s disease (e.g., selegiline) Mechanism of Action Inhibits monoamine oxidase enzymes, preventing the breakdown of neurotransmitters such as serotonin, norepinephrine, and dopamine, leading to increased concentrations of these neurotransmitters in the brain. Irreversible MAOIs Bind permanently to MAO enzymes and inhibit both MAO-A and MAO-B, leading to elevated levels of serotonin, norepinephrine, and dopamine in the brain. Reversible MAO-A Inhibitors Reversibly inhibit only MAO-A, primarily increasing serotonin and norepinephrine without affecting dopamine as much. Common MAOI Drugs Phenelzine: Non-selective, irreversible; used for depression Tranylcypromine: Non-selective, irreversible; rapid onset of action Isocarboxazid: Non-selective, irreversible; for treatment-resistant depression Moclobemide: Reversible, selective for MAO-A; used for major depression Selegiline: Used for Parkinson's disease and depression Rasagiline: Used primarily for Parkinson's disease Side Effects CNS Effects: Anxiety, insomnia, agitation, restlessness, dizziness, tremors CVS: Orthostatic hypotension, hypertensive crisis (especially when interacting with tyramine-containing foods ) GI Effects: Nausea, constipation Sexual Dysfunction: Decreased libido, anorgasmia Weight Gain: Common with irreversible MAOIs Serotonin Syndrome: When combined with other serotonergic drugs (SSRIs, TCAs, etc.) Contraindications Use with serotonergic agents (SSRIs, SNRIs, TCAs, etc.) due to risk of serotonin syndrome Use with sympathomimetic drugs due to hypertensive crisis risk Certain foods (high in tyramine) due to the risk of hypertensive crisis (cheese reaction) Cheese Reaction/ Tyramine induced Hypertensive Crisis MAOIs inhibit the breakdown of tyramine, an amino acid",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Mood Disorders-Mood Disorders"
    },
    {
      "q_no": 19,
      "question": "A 16-year-old male presents to the clinic with concerns about persistent bedwetting (nocturnal enuresis). His history reveals that this issue has led to depression and social withdrawal. After ruling out any organic causes, the physician decides to start pharmacological therapy. What is the most appropriate class of drug to manage both his depression and bedwetting?",
      "options": {
        "A": "Selective Serotonin Reuptake Inhibitors (SSRIs)",
        "B": "Tricyclic Antidepressants (TCAs)",
        "C": "Monoamine Oxidase Inhibitors (MAOIs)",
        "D": "Benzodiazepines"
      },
      "correct_answer": "B",
      "explanation": "Correct Answer: B) Tricyclic Antidepressants (TCAs) Explanation: Tricyclic Antidepressants (TCAs) such as imipramine are commonly used in the treatment of nocturnal enuresis in children and adolescents. They have anticholinergic properties that reduce bladder activity, thus helping with bedwetting. TCAs are also effective in treating depression, addressing both the emotional and enuretic aspects in this case. Tricyclic and Tetracyclic Antidepressants (TCAs and TeCAs): Primary Use Depression Other Uses Anxiety disorders, chronic pain, insomnia, OCD, nocturnal enuresis Mechanism of Action Inhibits reuptake of serotonin (5-HT) and norepinephrine (NE) by blocking transporters (SERT and NET) Receptor Antagonism Muscarinic receptors: Anticholinergic effects (dry mouth, blurred vision, constipation) H1 histamine receptors: Sedation, weight gain Alpha-1 adrenergic receptors: Postural hypotension Alpha-2 adrenergic receptors: NE feedback modification Voltage-sensitive sodium channels: Cardiotoxicity Tricyclic Antidepressants Clomipramine: Most serotonin-selective, used in OCD Amitriptyline: Depression, neuropathic pain Doxepin: Anxiety, insomnia Imipramine: Formerly used for nocturnal enuresis Desipramine: Most norepinephrine-selective Nortriptyline: Depression, chronic pain, diabetic neuropathy Viloxazine: Bicyclic antidepressant Tetracyclic Antidepressants Maprotiline Amoxapine: Also blocks D2 receptors, and may cause EPS Mianserin Side Effects Anticholinergic: Dry mouth, constipation, blurred vision, urinary retention, delirium Cardiac Side Effects: Tachycardia, flattened T waves, prolonged QT interval, ST depression, arrhythmias, cardiotoxicity Autonomic Side Effects: Postural hypotension (alpha-1 receptor blockade), risk of falls in elderly Neurological Side Effects: Tremors, seizures, extrapyramidal symptoms (EPS) from amoxapine. Endocrine Side Effects: Galactorrhea, gynecomastia Other Side Effects: Sedation, weight gain (H1 histamine receptor antagonism) Selective Serotonin Reuptake Inhibitors (SSRIs) (Option A) are primarily used for depression but have no direct benefit in managing nocturnal enuresis. Monoamine Oxidase Inhibitors (MAOIs) (Option C) are less commonly used in treating depression and are not indicated for nocturnal enuresis. Benzodiazepines (Option D) are primarily anxiolytics and sedatives, not suitable for treating nocturnal enuresis or depression in this context.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Mood Disorders-Mood Disorders"
    },
    {
      "q_no": 20,
      "question": "A 32-year-old male patient visits a psychiatrist complaining of recurrent panic attacks and significant anxiety in social situations. The patient is also previously diagnosed with depressive disorder. After a thorough assessment, the psychiatrist decides to start him on an SNRI. Which of the following medications is most appropriate for this patient’s condition?",
      "options": {
        "A": "Venlafaxine",
        "B": "Desvenlafaxine",
        "C": "Milnacipran",
        "D": "Levomilnacipran"
      },
      "correct_answer": "A",
      "explanation": "Correct Answer: A) Venlafaxine Explanation: Venlafaxine is indicated for both panic disorder and social phobia , making it the most appropriate choice for this patient’s symptoms. Selective Serotonin-Norepinephrine Reuptake Inhibitors (SNRI): Also referred to as dual reuptake inhibitors. Mechanism of Action Inhibit both serotonin transporters (SERT) and norepinephrine transporters (NET). Causes enhanced serotonergic and noradrenergic neurotransmission. Drugs and Uses Venlafaxine: (Option A) Major depression Generalized anxiety Panic disorder Social phobia Desvenlafaxine: (Option B) Major depression Duloxetine: Major depression Generalized anxiety Diabetic peripheral neuropathy Fibromyalgia Musculoskeletal pain Levomilnacipran: (Option D) Major depression Milnacipran: (Option C) Fibromyalgia Side Effects Neurological Side Effects: Insomnia Irritability Sexual Dysfunction: Decreased libido Erectile dysfunction Anorgasmia Ejaculatory delay Gastrointestinal Effects: Nausea Vomiting Diarrhea Withdrawal Symptoms: Dizziness Headache Nervousness Nausea Insomnia Dry mouth Reference: Kaplan & Sadock’s Synopsis of Psychiatry, 12th Edition, Pages 389, 626 Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 14th Edition, Pages 345, 350 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4008300/",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Mood Disorders-Mood Disorders"
    },
    {
      "q_no": 21,
      "question": "A 27-year-old nulliparous woman presents to the clinic with a history of recurrent mood disorder. As she and her partner plan to conceive in the near future, which of the following medications should be avoided in her treatment?",
      "options": {
        "A": "Sertraline",
        "B": "Paroxetine",
        "C": "Fluoxetine",
        "D": "Citalopram"
      },
      "correct_answer": "B",
      "explanation": "Correct answer: B)Paroxetine Explanation: Paroxetine has been linked to an increased risk of congenital heart defects when taken during the first trimester. It is classified as a Category D drug , making it the least safe option during pregnancy. SSRI in Pregnancy Discontinuing or modifying antidepressant regimens during pregnancy has relapse rates of major depression between 68% and 100%. Therefore it is necessary to continue antidepressants during pregnancy and postpartum to prevent depression relapse. SSRIs are used if postpartum blues persist or to prevent postpartum depression during pregnancy in at-risk women. Fetal outcomes SSRIs generally do not increase the risk of major congenital malformations, except for paroxetine . (Option B) Paroxetine , a Category D drug, is associated with increased heart defect risks when taken during the first trimester . Late pregnancy SSRI use can cause Poor neonatal adaptation syndrome (PNAS)- short term effect, may represent discontinuation syndrome with features such as poor muscle tone, sleep problems, crying, irritability, hypoglycemia, seizures. Late pregnancy SSRI use also carries a small risk (1-2 per 1,000 births) of Persistent pulmonary hypertension in newborns. Low Apgar score ADHD, Autism spectrum disorder Maternal outcomes SSRIs may impair platelet function and myometrial contractions, disrupting normal hemostasis and vasoconstriction, which can increase the risk of Postpartum hemorrhage . SSRIs can influence serotonin levels and inhibit nitric oxide synthesis , leading to vascular changes that elevate the risk of pre-eclampsia . SSRIs may worsen insulin resistance, increasing the risk of GDM during pregnancy. Minimal amounts of SSRIs are present in breast milk, with no reported harmful effects in breastfed babies. It is essential to inform patients of the potential risks and benefits of SSRI use during pregnancy and breastfeeding. Sertraline (Option B) : Considered one of the safer SSRIs during pregnancy, with no significant risks in the first trimester. Fluoxetine (Option B) : Regarded as relatively safe, with no pronounced risks highlighted for first-trimester use. Citalopram (Option B) : Shares a similar safety profile to sertraline and fluoxetine, with no specific risks compared to paroxetine. Reference: Kaplan and Sadock’s Synopsis of Psychiatry, 12th Edition, Pages 1979, 1980 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590209/",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Mood Disorders-Mood Disorders"
    },
    {
      "q_no": 22,
      "question": "A 32-year-old male presents with altered mental status, hyperreflexia,diarrhea and diaphoresis. He recently increased his dose of fluoxetine for depression and has started taking a new medication for his diffuse headaches. On examination, his vital signs reveal tachycardia and mild hypertension. Considering his recent medication changes, which of the following medications is most likely contributing to his current symptoms?",
      "options": {
        "A": "Ibuprofen",
        "B": "Sumatriptan",
        "C": "Metoprolol",
        "D": "Loratadine"
      },
      "correct_answer": "B",
      "explanation": "Correct Answer: B) Sumatriptan Explanation: The patient's symptoms, including altered mental status, hyperreflexia, diaphoresis, tachycardia, and mild hypertension, suggest a potential serotonin syndrome, which can occur with the combination of fluoxetine (SSRI) and sumatriptan (a triptan used for migraine treatment). Sumatriptan can increase serotonin levels and, when used with other serotonergic agents like fluoxetine, may lead to serotonin syndrome. Ibuprofen, metoprolol, and loratadine do not have a significant impact on serotonin levels and are unlikely to contribute to the patient's symptoms. Serotonin syndrome Definition Serotonin syndrome is a potentially life-threatening condition caused by excessive serotonergic activity in the central nervous system, typically due to the concurrent use of medications that increase serotonin levels or enhance serotonergic neurotransmission. Causes The syndrome is often triggered by concurrent use of SSRIs (Selective Serotonin Reuptake Inhibitors) with other medications: SSRIs: Selective Serotonin Reuptake Inhibitors that increase serotonin levels. MAOIs: Monoamine Oxidase Inhibitors that inhibit the breakdown of serotonin, leading to increased serotonin levels. L-Tryptophan: An amino acid precursor to serotonin that enhances serotonin synthesis. Lithium: Enhances the effects of serotonergic drugs, potentially leading to increased serotonin activity. Triptans: Medications for migraines that act on serotonin receptors (5-HT1B and 5-HT1D), increasing serotonin levels. Herbal Supplements: St. John’s Wort can induce serotonin syndrome when taken with SSRIs or other serotonergic agents. Pathophysiology The condition arises when the balance of serotonin production, release, and degradation is disrupted, leading to elevated serotonin levels in the synaptic cleft. This overstimulation of serotonin receptors, particularly 5-HT1A and 5-HT2A, results in various symptoms. Symptoms Autonomic Symptoms: Diarrhea Increased heart rate (tachycardia) High blood pressure (hypertension) Hyperthermia (elevated body temperature) Neuromuscular Symptoms: Restlessness and extreme agitation Myoclonus (rapid muscle contractions) Hyperreflexia (exaggerated reflex responses) Rigidity Cognitive Symptoms: Delirium or altered mental status Coma in severe cases Severe Outcomes: Cardiovascular collapse Seizures Potentially death if not treated promptly Treatment Discontinuation of Serotonergic Agents: All contributing medications should be",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Mood Disorders-Mood Disorders"
    },
    {
      "q_no": 23,
      "question": "A 28-year-old, recently married male presents with low self-esteem and concerns about premature ejaculation, which has caused distress and contributed to his depression and anxiety. His physician decides to prescribe a drug to manage his condition. Which of the following is the most appropriate drug in this case?",
      "options": {
        "A": "Dapoxetine",
        "B": "Sildenafil",
        "C": "Clomipramine",
        "D": "Alprazolam"
      },
      "correct_answer": "A",
      "explanation": "Correct Answer: A) Dapoxetine Explanation: Selective Serotonin Reuptake Inhibitors (SSRIs) , such as dapoxetine , are the most common treatment for premature ejaculation. They delay ejaculation by increasing serotonin levels, which affects the ejaculation reflex. Pharmacotherapy of depression: The pharmacotherapy of depression primarily involves antidepressant medications. These drugs work by influencing neurotransmitters in the brain, particularly serotonin, norepinephrine, and dopamine, which are thought to be imbalanced in depressive disorders. Major classes and medications used in treating depression : Class Examples Use SSRIs Fluoxetine, Sertraline, Escitalopram, Citalopram, Paroxetine First-line due to safety and tolerability SNRIs Venlafaxine, Duloxetine For those not responding to SSRIs Atypical Antidepressants Bupropion, Mirtazapine Less sexual dysfunction (Bupropion); helps insomnia (Mirtazapine) Tricyclic Antidepressants (TCAs) Amitriptyline, Nortriptyline For treatment-resistant cases Monoamine oxidase inhibitors (MAOIs) Phenelzine, Tranylcypromine Reserved for severe, resistant depression Adjunct Therapy Atypical antipsychotics, Lithium For treatment-resistant depression Treatment Duration: Acute Phase: Minimum of 6 months or length of previous episode (whichever is longer) Maintenance/Prophylaxis: Indicated for 3+ episodes or chronic depression (>2 years) SSRIs in the treatment of depression: Definition Selective Serotonin Reuptake Inhibitors (SSRIs) are a class of drugs primarily used to treat depression and other mental health conditions. They increase serotonin levels in the brain, which helps regulate mood, emotion, and sleep. Common SSRIs Sertraline Fluoxetine Paroxetine Citalopram Escitalopram Vilazodone (SPARI- Serotonin Partial Agonist and Reuptake Inhibitor) Fluvoxamine (mainly for OCD) Side Effects Gastrointestinal Nausea (most common) Diarrhea Anorexia Dry mouth Weight gain Constipation (especially with paroxetine) CNS Anxiety Insomnia Sedation Vivid dreams Emotional blunting Seizures (rare) Extrapyramidal symptoms Sexual Dysfunction (most common side effect in long-term use) Decreased libido Delayed ejaculation Inhibited orgasm Hematological Impaired platelet aggregation Increased risk of GI bleeding (especially with NSAIDs) Miscellaneous Hyponatremia Allergic rashes Hyperprolactinemia (leading to galactorrhea or menstrual irregularities) Sildenafil (Option B) is a phosphodiesterase type 5 Inhibitor used for erectile dysfunction and does not address premature ejaculation. Clomipramine (Option C) is a tricyclic antidepressant that helps with premature ejaculation, but not the first-line treatment due to potential side effects;",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Mood Disorders-Mood Disorders"
    },
    {
      "q_no": 24,
      "question": "A 35-year-old woman visits the clinic after experiencing persistent sadness, increased anxiety, and sleep disturbances for the past month. She recently went through a traumatic event involving the loss of a loved one. She reports feeling overwhelmed and unable to cope with her emotions. What type of depression is she most likely experiencing?",
      "options": {
        "A": "Endogenous Depression",
        "B": "Exogenous Depression",
        "C": "Persistent Depressive Disorder",
        "D": "Major Depressive Disorder with Psychotic Features"
      },
      "correct_answer": "B",
      "explanation": "Correct answer: B)Exogenous Depression Explanation: Symptoms are triggered by a specific life event (the loss of a loved one), aligning with the characteristics of Exogenous (reactive) depression. Endogenous Depression and Exogenous (Reactive) Depression Feature Endogenous Depression (Option A) Exogenous (Reactive) Depression (Option B) Definition Primarily caused by biological factors. Arises due to psychological or environmental factors. Precipitating Events Manifests without identifiable precipitating events. Triggered by specific life events (e.g., loss, trauma). Symptoms Characterized by melancholic or psychotic features. Exhibits multiple somatic complaints and emotional distress. Mood Regulation Linked to genetic or neurochemical factors affecting mood. Relates to an individual's emotional response to their circumstances. Treatment Response Often requires pharmacological treatment (e.g., antidepressants). May respond well to psychotherapy and counseling focused on coping strategies. Duration Symptoms can be persistent and chronic. Symptoms may be more acute and linked to the duration of the triggering event. Persistent Depressive Disorder (Option C) requires symptoms to persist for 2 or more years without symptom-free periods lasting longer than 2 months, whereas the patient’s symptoms are acute and linked to a specific recent triggering event. Major Depressive Disorder with Psychotic Features (Option D) requires the presence of psychotic symptoms (such as delusions or hallucinations) alongside major depressive symptoms. The patient's symptoms do not indicate psychosis, making this option inappropriate. Reference: Reference: https://www.nimh.nih.gov/health/topics/depression Kaplan and Sadock’s Synopsis of Psychiatry, 12th Edition, Page 175",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Mood Disorders-Mood Disorders"
    },
    {
      "q_no": 25,
      "question": "A 32-year-old female patient has been complaining of persistent sadness, fatigue, and difficulty concentrating over the past few months. Upon examination, you notice several physical signs on her face, which are shown below (asterisk). Identify the sign shown in the image.",
      "options": {
        "A": "Veraguth's Fold",
        "B": "Omega Sign",
        "C": "Chandler’s Sign",
        "D": "Dennie-Morgan Lines"
      },
      "correct_answer": "B",
      "explanation": "Correct Answer: B) Omega Sign Explanation: The omega sign , an omega-shaped fold on the forehead from excessive use of the corrugator muscle, reflects emotional stress and is indicative of depressive disorders. Physical Signs of Depression: Veraguth's Fold (Option A) Omega Sign (Option B) A triangular fold in the inner corner of the upper eyelid due to changes in the corrugator and zygomatic muscles from prolonged muscle tension associated with depression. An omega-shaped fold on the forehead reflecting excessive use of the corrugator muscle, indicative of emotional stress related to depressive disorders. Chandler’s Sign (Option C): Is associated with ocular conditions, specifically describing a finding related to an eye movement or appearance, particularly in certain cases of ophthalmic disorders like orbital cellulitis. It refers to the presence of a swollen, edematous eyelid along with proptosis and restricted ocular movement, often seen in serious orbital infections. This sign is not relevant to psychiatric or depressive disorders. Dennie-Morgan Lines (Option D): These are",
      "image": "https://raw.githubusercontent.com/tk22kalal/mcqimage/main/pxpsychiatry/Mood_Disorders-Mood_Disorders_Q25_q.png",
      "explanation_image": null,
      "chapter_heading": "Mood Disorders-Mood Disorders"
    },
    {
      "q_no": 26,
      "question": "A 32-year-old female presents to the clinic with persistent low mood, increased appetite, and excessive sleeping. She reports that her mood tends to improve temporarily in response to positive events and that she has heightened sensitivity to rejection. Which of the following treatments is least appropriate for her condition?",
      "options": {
        "A": "Monoamine oxidase inhibitors (MAOIs)",
        "B": "Selective serotonin reuptake inhibitors (SSRIs)",
        "C": "Tricyclic antidepressants (TCAs)",
        "D": "Cognitive-behavioral therapy (CBT)"
      },
      "correct_answer": "C",
      "explanation": "Correct Answer: C) Tricyclic antidepressants (TCAs) Explanation: Symptoms of mood reactivity, increased appetite, hypersomnia, and rejection sensitivity align with diagnosis of Atypical Depression. TCAs are less effective in treating atypical depression compared to other antidepressants. They are associated with more significant side effects, such as sedation and weight gain, which can worsen the symptoms of this subtype of depression. Atypical Depression : It is a subtype of major depressive disorder (MDD) characterized by mood reactivity (the ability to feel a temporary mood lift in response to positive events) and a distinct set of other symptoms. Despite the name, it is one of the more common forms of depression. It tends to begin earlier in life and is more common in women. According to DSM-5, atypical features can occur in both MDD and persistent depressive disorder (dysthymia). Features of Atypical Depression (DSM-5): Mood Reactivity: A defining feature of atypical depression, where the individual's mood brightens significantly in response to positive events (e.g., good news). Leaden Paralysis: A heavy, lead-like feeling in the limbs that results in extreme fatigue and physical sluggishness. Hypersomnia: Excessive sleeping, usually more than 10 hours per day, or difficulty staying awake during the day, which contrasts with the early morning awakening seen in melancholic depression. Increased Appetite and Weight Gain: Unlike other forms of depression that may cause weight loss, individuals with atypical depression often experience an increase in appetite and significant weight gain. Interpersonal Rejection Sensitivity: The patient experiences extreme sensitivity to interpersonal rejection, often feeling hurt or rejected by others, which may interfere with their social or occupational functioning. Distinctive Characteristics: Mood Reactivity: Unlike melancholic depression, mood improves temporarily after positive events. Comorbid Anxiety: Higher rates of co-occurring anxiety disorders. Earlier Onset: Typically begins earlier in life than other depressive subtypes. Treatment: Monoamine Oxidase Inhibitors (MAOIs) (Option A), like phenelzine, were historically effective for atypical depression but are less used now due to dietary restrictions (cheese reaction). Selective Serotonin Reuptake Inhibitors (SSRIs) (Option B), such as fluoxetine, are more commonly prescribed and effective for many. Cognitive Behavioral Therapy (CBT) (Option D) is also beneficial, especially for addressing rejection sensitivity and mood instability in atypical depression.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Mood Disorders-Mood Disorders"
    },
    {
      "q_no": 27,
      "question": "A 50-year-old woman presents with severe depression, marked by sadness, loss of interest, and recent episodes of immobility and unresponsiveness. She maintains bizarre postures and shows minimal verbal response, with low mood and agitation during episodes. Which diagnosis is most appropriate?",
      "options": {
        "A": "Depression with melancholic features",
        "B": "Atypical depression",
        "C": "Depression with catatonic features",
        "D": "Major depressive disorder with psychotic features"
      },
      "correct_answer": "C",
      "explanation": "Correct Answer: C) Depression with catatonic features Explanation: The most appropriate diagnosis is Depression with catatonic features , as the patient exhibits marked immobility, bizarre postures, and minimal verbal response, characteristic of this subtype. Depression with catatonic features (Option C) is a rare but severe subtype of major depressive disorder characterized by marked motor disturbances. According to DSM-5, catatonic features can occur in the context of several mental disorders, including major depressive disorder (MDD), and involve extreme physical immobility or excessive motor activity. These features are linked with increased morbidity and require prompt treatment. Features of Depression with Catatonic Features: Stupor: A marked decrease in reactivity to the environment, where the patient may appear unresponsive and immobile. Catalepsy: Passive induction of a posture held against gravity where the patient holds a fixed posture for an extended period. Waxy flexibility: slight, even resistance to positioning by examiner. Mutism: Little or no verbal response despite prompts. Negativism: An opposition or lack of response to instructions or external stimuli. Posturing: Spontaneous maintenance of a rigid or bizarre posture. Stereotypies: Repetitive, non-goal-directed movements (e.g., hand flapping or grimacing). Mannerisms: repetitive, odd, purposeful movements. Agitation: Excessive and purposeless motor activity not influenced by external stimuli. Echolalia or Echopraxia: Repetition of another's words (echolalia) or movements (echopraxia). Distinctive Characteristics: Motor Symptoms: The defining aspect of catatonic depression is its effect on movement, with patients either becoming immobile or, in contrast, exhibiting hyperactivity. Treatment: First-line treatment involves benzodiazepines (e.g., lorazepam), which are effective in alleviating catatonic symptoms. Electroconvulsive therapy (ECT) is also highly effective and often used in patients who do not respond to pharmacotherapy or when rapid resolution is required. Depression with melancholic features (Option A) is a severe subtype of major depressive disorder, often seen in older adults. It is marked by a profound lack of pleasure in all or nearly all activities and a failure to respond to pleasurable stimuli (anhedonia). Melancholic features include: A distinct quality of depressed mood- profound despondency, despair, empty mood. Psychomotor Disturbance: Either agitation or retardation. Excessive Guilt: Feelings of worthlessness, often out of proportion to reality. Early Morning Awakening: Waking up at least two hours earlier than usual. Mood Worse in the Morning: A clear diurnal variation, where the mood is worse in the early part of the day. Anorexia/Weight",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Mood Disorders-Mood Disorders"
    },
    {
      "q_no": 28,
      "question": "A 50-year-old woman presents with a 2-year history of sadness and loss of interest in activities, along with recent episodes of hallucinations lasting 1-2 weeks. Her mood remains low between these episodes. Which of the following statements in this scenario is/are true? Statement 1: Monotherapy with tricyclic antidepressants (TCA) is effective. Statement 2: A combination of antidepressants and antipsychotics is the treatment of choice. Statement 3: Patient likely to have schizoaffective disorder since she experiences both mood and psychotic symptoms. Statement 4: Electroconvulsive therapy is the treatment of choice with severe psychotic symptoms and high suicide risk.",
      "options": {
        "A": "1, 2, and 4",
        "B": "2 and 4",
        "C": "2, 3, and 4",
        "D": "1 and 4"
      },
      "correct_answer": "B",
      "explanation": "Correct Answer: B) 2 and 4 Explanation: The clinical scenario here points to major depressive disorder with psychotic symptoms. The two preferred choices of treatment are the combination of antidepressants and antipsychotics, and electroconvulsive therapy (with high remission rates of up to 95%). Patients with Major Depressive Disorder with Psychotic Features experience psychotic symptoms only during mood episodes. In contrast, schizoaffective disorder requires at least 2 weeks of only psychotic symptoms (delusions and hallucinations) without mood symptoms (Statements 3 ruled out). Definition Major depression disorder (MDD) with psychotic features includes mood disturbance with delusions, hallucinations, or both. Prevalence Occurs in approximately 18.5% of MDD patients and increases with age. Characteristics Higher treatment resistance More suicide attempts Longer illness duration Greater functional impairment Higher relapse rates Geriatric Considerations Patients often show significant cognitive dysfunction; depressive pseudodementia may develop. Cognitive Impairment Combination therapy : antidepressants + antipsychotics or ECT is the standard of care. Treatment Approaches Monotherapy with SSRIs or TCAs is less effective . (Statements 1 ruled out) Efficacy of ECT ECT shows high remission rates (up to 95% in psychotic depression) compared to pharmacotherapy. ECT is first line treatment in case of severe psychotic symptoms and high suicide risk. Reference: Kaplan and Sadock’s Synopsis of Psychiatry, 12th Edition, Page 1954. Diagnostic and Statistical Manual of Mental Disorders, 5th Edition, Page 186. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3572511/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181862/# https://www.ncbi.nlm.nih.gov/books/NBK541012/",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Mood Disorders-Mood Disorders"
    },
    {
      "q_no": 29,
      "question": "A 22-year-old patient is experiencing sadness, hopelessness, anhedonia, fatigue, and low energy. During the examination, she reports a sad mood and she appears agitated. What is the required duration of these symptoms for a diagnosis of depression?",
      "options": {
        "A": "3 weeks",
        "B": "2 months",
        "C": "1 week",
        "D": "2 weeks"
      },
      "correct_answer": "D",
      "explanation": "Correct Answer: D) 2 weeks Explanation: The clinical scenario has more than five symptoms of major depressive disorder with both depressed mood and anhedonia, and for its diagnosis, the symptoms must persist for the next 2 weeks . Symptoms Depressed Mood/ sadness Anhedonia: Inability to experience pleasure in activities once enjoyed Low energy, easy fatigability Sleep disturbances: Usually, insomnia (especially early morning awakening, prolonged sleep latency, increased intermittent awakenings ) Reduced latency of REM sleep Excessive guilt feelings Poor concentration and negative cognitions (negative thoughts) Poor appetite and associated weight loss (in some cases, weight gain can be seen) Psychomotor retardation/agitation Suicidal thoughts Atypical Depression: Mood reactivity (ability to feel better with positive events) and at least two of the following: hyperphagia, hypersomnia, leaden paralysis, or long-standing rejection sensitivity. Diagnosis: Five or more of the symptoms present during the same 2 - week period and represent a change from previous functioning; At least one of the symptoms is either depressed mood or loss of interest or pleasure . Recurrent depressive disorder: When there are 2 or more episodes of symptoms of depression, with a minimum of 2 months between episodes, it is called recurrent depressive disorder. Reference: Kaplan and Sadock’s Synopsis of Psychiatry, 12th Edition, Pages 1215-1219, 1223. https://www.who.int/news-room/fact-sheets/detail/depression https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6386825/# https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2990566/#",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Mood Disorders-Mood Disorders"
    },
    {
      "q_no": 30,
      "question": "Which of the following is not a component of the “Beck’s cognitive triad”?",
      "options": {
        "A": "Negative self-perception",
        "B": "Perception of the environment as hostile",
        "C": "Expectations of suffering and failure in the future",
        "D": "Introjection of lost significant object"
      },
      "correct_answer": "D",
      "explanation": "Correct Answer: D) Introjection of lost significant object Explanation: The introjection of lost objects is a part of the psychodynamic theory of depression, while the cognitive triad is a component of the cognitive theory, involving self - perception , environment, and the future . Psychosocial Theories of Depression Life Events and Environmental Stress Stressful life events often precede the first episode of mood disorders. Initial stress may lead to long-lasting biological changes, increasing the risk for future episodes even without further stressors. Psychodynamic Theories Early disturbances in the infant-mother relationship predispose to depression. Depression is linked to real or imagined loss of significant objects. Introjection of lost objects serves as a defense mechanism. Feelings of love and hate toward the lost object result in self-directed anger. Cognitive Theory Depression arises from cognitive distortions known as depressogenic schemata. Cognitive Triad (by Aaron Beck): Worthlessness: Negative self-perception. (Option A) Helplessness: Perception of the environment as hostile and demanding. (Option B) Hopelessness: Expectation of suffering and failure in the future. (Option C) Therapy focuses on modifying these cognitive distortions. Learned Helplessness Developed from studies showing that exposure to uncontrollable stressors (e.g., electric shocks in dogs) leads to passive behavior. Humans may internalize helplessness and lose self-esteem after adverse events. Improvement in depression involves learning a sense of control and mastery over one’s environment. Evolutionary Theory Depression is viewed as an adaptive response to perceived environmental threats. Withdrawal from social situations and decreased activity may serve as protective mechanisms. Reference: Kaplan and Sadock’s Synopsis of Psychiatry, 12th Edition, Pages 1278-1282",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Mood Disorders-Mood Disorders"
    },
    {
      "q_no": 31,
      "question": "Match the following genes involved in the development of depression with their normal functions. Genes Encoded for A) SLC6A4 i) Serotonin receptor B) DRD4 ii) Dopamine transporter C) HTR1A iii) Serotonin transporter D) SLC6A3 iv) Dopamine receptor",
      "options": {
        "A": "a-ii, b-iv, c-i, d-iii",
        "B": "a-iii, b-iv , c-i, d-ii",
        "C": "a-ii, b-i, c-iv , d-iii",
        "D": "a-i, b-ii, c-iii, d-iv"
      },
      "correct_answer": "B",
      "explanation": "Correct Answer: B) a-iii, b-iv, c-i, d-ii Explanation: Genetic Influence About one-third of major depression risk is attributed to genetic factors. The gene encoding of serotonin receptor : HTR1A The gene for serotonin transporter : 5HTTP / SLC6A4 The gene for dopamine receptor : DRD4 The gene for dopamine transporter : SLC6A3 Family History Risk increases 2.5–3 times if a first-degree relative has depression. Life events can raise risk from 5 to 16 times shortly after occurrence. Neurobiological Mechanisms Studies show that individuals with the short allele of 5-HTTLPR (serotonin transporter gene) exhibit amygdala hyperreactivity to emotional threats Reference: Kaplan and Sadock’s Synopsis of Psychiatry, 12th Edition, Page 1274 https://www.ncbi.nlm.nih.gov/books/NBK215119/",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Mood Disorders-Mood Disorders"
    }
  ]
}
